Literature DB >> 6332671

Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.

B Sheid, J Boyce.   

Abstract

Ascitic fluid from women with advanced ovarian carcinomas was shown to contain factor(s) which inhibit(s) T lymphocyte mitogenesis. The factor(s) was (were) demonstrated to be associated with the infiltrating macrophages. The inhibition was reversible and inhibited mitogenesis at some late event in the cell cycle. The inhibitory substance(s) was (were) noncytotoxic, dialyzable, heat-stable at 70 degrees C for 10 min (but unstable at 100 degrees C for 15 min), and partially resistant to protease treatment (55%-70%). Further experiments demonstrated that macrophages isolated from the ascitic fluid of patients with cirrhosis of the liver also released factor(s) which inhibit(s) T lymphocyte mitogenesis. On the basis of our data and data from other investigators, we propose that in advanced human ovarian cancer of epithelial origin, macrophages which infiltrate the ascitic fluid elaborate nonspecific inhibitors of T lymphocyte blastogenesis within the proximal environment, resulting in localized immunosuppression and the subsequent enhancement of metastasis within the peritoneal cavity, the tumor cells themselves being resistant to the cytocidal action of the macrophages due to genetic selection and/or their inherent biochemical ability to circumvent normal immunosurveillance mechanisms. This may account, at least in part, for the rapid metastasis and poor prognosis of human ovarian adenocarcinomas.

Entities:  

Mesh:

Year:  1984        PMID: 6332671     DOI: 10.1007/bf00205484

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  28 in total

1.  SEPARATION OF WHITE BLOOD CELLS.

Authors:  A BOYUM
Journal:  Nature       Date:  1964-11-21       Impact factor: 49.962

2.  Macrophage content of tumours in relation to metastatic spread and host immune reaction.

Authors:  S A Eccles; P Alexander
Journal:  Nature       Date:  1974-08-23       Impact factor: 49.962

3.  Characterization of a dialyzable immunosuppressive fraction from mastocytoma culture supernatants (39901).

Authors:  I Kamo; H Friedman
Journal:  Proc Soc Exp Biol Med       Date:  1977-10

4.  Specific inhibition of lymphocyte blastogenic responses to mitogens by a factor produced by cultured human malignant lymphoma cells.

Authors:  E M Hersh; B Drewinko
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

5.  Characterization of tumor lines derived from spontaneous metastases of a transplanted murine sarcoma.

Authors:  A Mantovani; R Giavazzi; G Alessandri; F Spreafico; S Garattini
Journal:  Eur J Cancer       Date:  1981-01       Impact factor: 9.162

Review 6.  Immune deficiency states associated with malignant disease in man.

Authors:  J Harris; R C Bagai
Journal:  Med Clin North Am       Date:  1972-03       Impact factor: 5.456

Review 7.  Immunologic approaches to the diagnosis of cancer.

Authors:  R B Herberman
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

8.  Augmentation of metastasis formation by thioglycollate-elicited macrophages.

Authors:  E Gorelik; R H Wiltrout; M J Brunda; H T Holden; R B Herberman
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

9.  Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin.

Authors:  G Peri; N Polentarutti; C Sessa; C Mangioni; A Mantovani
Journal:  Int J Cancer       Date:  1981-08-15       Impact factor: 7.396

10.  Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients with ascites ovarian tumors.

Authors:  A Mantovani; N Polentarutti; G Peri; Z B Shavit; A Vecchi; G Bolis; C Mangioni
Journal:  J Natl Cancer Inst       Date:  1980-06       Impact factor: 13.506

View more
  2 in total

Review 1.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?

Authors:  Antonio Macciò; Sara Oppi; Clelia Madeddu
Journal:  J Ovarian Res       Date:  2021-02-08       Impact factor: 4.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.